No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Healthcare Plans
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
www.cvshealth.comNo one on the platform currently holds 0HRS.L.
No tracked institution reports a position in 0HRS.L as of their last filing.
No one on the platform has traded 0HRS.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.3% | 7.4% | 7.0% | — | — | — |
| Rev. Growth % | 7.9% | 8.4% | ||||
| Profit Margin % | 0.4% | 1.6% | 2.0% | |||
| Free Cash Flow Margin % | 1.9% | 3.2% | 3.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $416.1B | +4.0% | $8.00 | $7.73–$8.39 | — | 1 |
| 2027 | $429.2B | +3.2% | $8.51 | $8.22–$8.92 | — | 1 |
| 2028 | $448.8B | +4.6% | $9.71 | $9.38–$10.18 | — | 1 |
| 2029 | $473.6B | +5.5% | $10.87 | $10.50–$11.40 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $1.85 | $2.58 | +39.5% |
| 2026-05-06 | $2.18 | $2.57 | +17.9% |
| 2026-02-10 | $1.00 | $1.09 | +9.0% |
| 2025-10-29 | $1.37 | $1.60 | +16.8% |
| 2025-07-31 | $1.46 | $1.81 | +24.0% |
| 2025-05-01 | $1.70 | $2.25 | +32.4% |
| 2025-02-12 | $0.91 | $1.19 | +30.2% |
| 2024-11-06 | $1.44 |
| $1.09 |
| -24.3% |
| -4.50% |
| $47.5B |
| — |
| 0JZU.LMcKesson Corporation | $894.24 | -0.99% | $110.5B | — |
| 0QZU.LVertex Pharmaceuticals Incorporated | $521.00 | +0.45% | $133.1B | — |
Source: Financial Modeling Prep · peers by sector/industry